Epacadostat
- Generic Name
- Epacadostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H13BrFN7O4S
- CAS Number
- 1204669-58-8
- Unique Ingredient Identifier
- 71596A9R13
- Background
Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer
Phase 2
Completed
- Conditions
- Malignant Ovarian Clear Cell TumorRecurrent Ovarian Carcinoma
- Interventions
- Drug: EpacadostatBiological: Pembrolizumab
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 14
- Registration Number
- NCT03602586
- Locations
- 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Grant Medical Center, Columbus, Ohio, United States
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
Phase 1
Completed
- Conditions
- Prostate CancerSolid TumorMetastatic Prostate CancerAdvanced Solid TumorProstate Neoplasm
- Interventions
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT03493945
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Early Phase 1
Completed
- Conditions
- Stage III Ovarian Cancer AJCC v6 and v7Stage III Primary Peritoneal Cancer AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IV Ovarian Cancer AJCC v6 and v7Stage III Fallopian Tube Cancer AJCC v7Stage IIIA Primary Peritoneal Cancer AJCC v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIB Ovarian Cancer AJCC v6 and v7Stage IIIA Ovarian Cancer AJCC v6 and v7
- Interventions
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT02042430
- Locations
- 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath